tiprankstipranks
Trending News
More News >

Fosun Pharma Advances Pediatric Glioma Treatment with New Clinical Trial

Story Highlights
Fosun Pharma Advances Pediatric Glioma Treatment with New Clinical Trial

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical’s subsidiary has initiated a Phase III clinical trial for Luvometinib Tablets, targeting children with low-grade glioma in China. This development highlights the company’s ongoing commitment to advancing innovative treatments and could potentially strengthen its position in the pharmaceutical market, offering new hope for pediatric patients with this condition.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on developing innovative drugs, with a market emphasis on treatments for various diseases, including cancer and neurological disorders.

Average Trading Volume: 6,887,271

Technical Sentiment Signal: Buy

Current Market Cap: HK$67.49B

For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1